Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
12don MSN
Early HIV drugs give immune system a brief reprieve before dysregulation returns, study finds
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.
APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...
News Medical on MSN
Medicaid Expansion Increases Access to HIV Prevention Medication for High-Risk Populations
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
News-Medical.Net on MSN
Investigating the impact of starting HIV drugs within days of infection
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at ...
Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback